AVLN

Avalyn Pharma Inc.

Healthcare · Biotechnology

28.10$ +0.0% vs. previous close Closing price · As of: Oct 2, 2026

Statements

Income Statement

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size % Per share

Last 12 Full history

Download as CSV

All figures per share in USD.

Tick rows to compare them in a chart (up to 4)

Income Statement AVLN
Line item	2024	2025
Revenue	0.00	0.00
Research & Development	1.09	1.83
Selling, General & Administrative	0.27	0.35
Total Operating Expenses	1.37	2.18
Operating Income	-1.37	-2.18
Pre-Tax Income	-1.19	-2.04
Net Income	-1.19	-2.04
EBITDA	-1.37	-2.18

Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.